EUVIMEDEUVIMED entdecken
Crossref

FeNO as a Treatable Trait in Chronic Cough: Insights from the PROCOUGH Study

Mustafaa Wahab, Elena Kum, Nermin Diab, Danica Brister, Ana Oliveira, Wafa Hassan, Sue Beaudin, Catie Stevens, Jennifer Wattie, Lesley Wiltshire, Karen Howie, Kieran Killian und 4 weitere

Lung · 15.07.2026 · 204 (1)

DOI: 10.1007/s00408-026-00913-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lung, online erschienen am 15.07.2026. Verfasst von Mustafaa Wahab und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University, Hamilton, ON, Canada. Hauptthemen laut MEDLINE: Chronic Cough, Asthma, Adrenergic beta-2 Receptor Agonists, Nitric Oxide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Merck Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Type 2 (T2) inflammatory biomarkers are established therapeutic targets in asthma and non-asthmatic eosinophilic bronchitis (NAEB), but their relevance in chronic cough remains unclear. Therefore, the objective of our study was to evaluate the relationship between T2 biomarkers and cough outcomes, and to determine their ability to predict treatment response and cough control. METHODS: This post-hoc analysis of the prospective PROCOUGH cohort included 100 patients with chronic cough. Patients underwent comprehensive phenotyping and were classified as chronic cough secondary to asthma/NAEB (CCAst/EB) or refractory chronic cough (RCC). Patients with CCAst/EB received inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) therapy, while those without evidence of T2 inflammation or who had failed ICS/LABA were treated with neuromodulators. Cough outcomes included 24-h cough frequency, Leicester cough questionnaire (LCQ), and cough severity visual analogue scale (VAS). Baseline and post-treatment FeNO, blood eosinophils, and sputum eosinophils were measured. Correlation, logistic regression, and receiver operating characteristic (ROC) analyses were performed. RESULTS: Baseline FeNO and sputum eosinophils were higher in CCAst/EB than RCC. In CCAst/EB, ICS/LABA treatment reduced FeNO and sputum eosinophils and improved cough frequency, LCQ, and VAS. However, only changes in FeNO correlated with changes in cough frequency (r = 0.43, p = 0.007). In multivariable analysis, baseline FeNO independently predicted cough control (OR 1.03, 95% CI 1.00-1.05). FeNO demonstrated modest discriminatory ability for predicting treatment response (AUC = 0.73) and cough control (AUC = 0.75), with an optimal threshold of approximately 26 ppb. CONCLUSION: FeNO represents a modest predictor of treatment response and cough control in chronic cough but not RCC. These findings support its role as a treatable trait.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chronic CoughAsthmaAdrenergic beta-2 Receptor AgonistsNitric OxideAdrenal Cortex HormonesBronchitisCoughHumansFemaleMaleBiomarkersSputumEosinophilsMiddle AgedProspective StudiesTreatment OutcomeAdultAdministration, InhalationSeverity of Illness IndexEosinophiliaPhenotypeChronic DiseaseFractional Exhaled Nitric Oxide Testing

Stichwörter der Autor:innen

BiomarkersChronic coughFractional exhaled nitric oxideRefractory chronic coughTreatable traitsType 2 inflammation

Substanzen

BiomarkersAdrenergic beta-2 Receptor AgonistsNitric OxideAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
  • Department of Medicine, The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada.
  • Department of Medicine, University of Calgary, Calgary, AB, Canada.
  • Respiratory Research and Rehabilitation Laboratory (Lab3R), School of Health Sciences (ESSUA), University of Aveiro, Aveiro, Portugal.
  • iBiMED -Institute of Biomedicine, Department of Medical Sciences, University of Aveiro, Aveiro, Portugal.

Förderung

  • Merck Canada

Zitieren

APA

Wahab, M., Kum, E., Diab, N., Brister, D., Oliveira, A., Hassan, W., Beaudin, S., Stevens, C., Wattie, J., Wiltshire, L., Howie, K., Killian, K., Sehmi, R., Gauvreau, G. M., O'Byrne, P. M., & Satia, I. (2026). FeNO as a Treatable Trait in Chronic Cough: Insights from the PROCOUGH Study. Lung, 204(1). https://doi.org/10.1007/s00408-026-00913-y

Vancouver

Wahab M, Kum E, Diab N, Brister D, Oliveira A, Hassan W, et al. FeNO as a Treatable Trait in Chronic Cough: Insights from the PROCOUGH Study. Lung. 2026;204(1). doi:10.1007/s00408-026-00913-y

BibTeX
@article{Wahab2026,
  author = {Wahab, Mustafaa and Kum, Elena and Diab, Nermin and Brister, Danica and Oliveira, Ana and Hassan, Wafa and Beaudin, Sue and Stevens, Catie and Wattie, Jennifer and Wiltshire, Lesley and Howie, Karen and Killian, Kieran and Sehmi, Roma and Gauvreau, Gail M and O'Byrne, Paul M and Satia, Imran},
  title = {FeNO as a Treatable Trait in Chronic Cough: Insights from the PROCOUGH Study},
  journal = {Lung},
  year = {2026},
  volume = {204},
  number = {1},
  doi = {10.1007/s00408-026-00913-y}
}
Kostenlos starten →